North America HPV Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Sample, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
North America · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$617.7 MnPlaceholder estimate
Estimate 2025$686.3 Mn42.1% of the global market
Projected 2034$1.77 Bn 157.9%Adds $1.08 Bn over 9 forecast years
CAGR 2025–203411.1%Faster than 75% of 173 Medical Devices markets here
Key players5
North America is 42.08% of the global market.
Among regions, the largest is North America (this report) at $686.3 Mn.
56 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The North America HPV Testing Market Analysis Executive Summary
HPV testing detects human papillomavirus types that can cause cervical cancer, used for cervical screening, including self-collected samples.
Key segments of the HPV Testing market include test (HPV DNA Tests, HPV mRNA Tests and Genotyping Tests) and sample (Clinician-Collected and Self-Collected).
North America HPV Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
North America HPV Testing Market Dynamics
Market Growth Drivers
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the HPV Testing market. New products designed around women's biology and digital care are improving access.
Opportunity
Femtech, personalised care and new treatments for under-served conditions open strong growth for the HPV Testing market, especially as employers and payers add women's health benefits.
Market Restraints
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the HPV Testing market.
Competitive Landscape for HPV Testing Market in North America
The HPV Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for HPV Testing Market in North America
HPV Testing in North America: rules, payment and research
In the countries we cover here, medical devices are regulated by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4]. ClinicalTrials.gov lists 56 studies on HPV Testing that are recruiting, active or about to start in North America.[5]
[5]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how HPV Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in North America.
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in HPV Testing right now, from free public sources.
Clinical trials
56 active trials in US and Canada
Recruiting, about to start, or running now. Counted across the 2 countries we report on in North America.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the HPV Testing market in North America?
Placeholder estimate: about $686.3 Mn in 2025, rising to about $1.77 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the HPV Testing market in North America growing?
Placeholder estimate: about 11.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the HPV Testing market report cover?
The report splits the market by test (HPV DNA Tests, HPV mRNA Tests, Genotyping Tests), sample (Clinician-Collected, Self-Collected) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the HPV Testing market?
Key players include Roche Diagnostics, Hologic, Inc., Qiagen N.V., BD (Becton, Dickinson) and Abbott Laboratories.
What is driving the HPV Testing market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the HPV Testing market. New products designed around women's biology and digital care are improving access.
How many clinical trials on HPV Testing are running in North America?
56 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on HPV Testing?
PubMed lists 1,549 papers on HPV Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
Canada
China
Japan
Germany
UK
France
Italy
Brazil
Spain
Ecuador
India
Saudi Arabia
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Singapore
Kenya